Back to Search
Start Over
Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains
- Source :
- Journal of Global Antimicrobial Resistance. 19:241-251
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Objectives: Bacterial viability and enrichment of resistance resulting from three different amikacin administration schedules with respect to haemodialysis (HD) were assessed against three OXA-48-producing Klebsiella pneumoniae isolated during an outbreak in a Spanish hospital. Methods: A previously described two-compartment dynamic system was used. Three possible amikacin administration schedules were simulated: (i) haemodialysis immediately after amikacin infusion (pre-HD); (ii) infusion immediately after haemodialysis (post-HD); and (iii) infusion at 50% interdialytic period. Amikacin standard dose (SD) and double dose (DD) were simulated for each schedule. Values of Cmax/MIC, Cmax/MPC (mutant prevention concentration), AUC0-48h/MIC, AUC0-48h/MPC and %TMSW (percentage of time that the concentration was inside the mutant selection window) were determined with experimental data and were correlated with the area under the bacterial killing curve of the total population and the resistant subpopulation. Results: Both with SD and DD, the pre-HD schedule resulted in increases at 48h in bacterial counts of the total population at the expense of enrichment of pre-existing resistant subpopulations from 12h onwards for all strains. The estimated %TMSW that prevented enrichment of resistant mutants was
- Subjects :
- 0301 basic medicine
Microbiology (medical)
Veterinary medicine
Time Factors
Klebsiella pneumoniae
Farmacología
030106 microbiology
Immunology
Cmax
Microbial Sensitivity Tests
Microbiology
Drug Administration Schedule
beta-Lactamases
03 medical and health sciences
0302 clinical medicine
Renal Dialysis
medicine
Humans
Immunology and Allergy
Computer Simulation
030212 general & internal medicine
Amikacin
Diálisis renal
Cross Infection
Microbial Viability
Medicamento
biology
business.industry
Double dose
biology.organism_classification
Time optimal
In vitro
Anti-Bacterial Agents
Klebsiella Infections
Efectos fisiológicos
Spain
Pharmacodynamics
Toxicity
Amicacina
business
medicine.drug
Subjects
Details
- ISSN :
- 22137165
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Journal of Global Antimicrobial Resistance
- Accession number :
- edsair.doi.dedup.....5a929db1d3c77f9bf4ec64d263ff5a6a
- Full Text :
- https://doi.org/10.1016/j.jgar.2019.05.027